64Cu-DOTA Pembrolizumab for Imaging Metastatic Solid Tumors in Patients Receiving Stereotactic Body Radiation

NCT05728372 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped withdrawn per PI

Conditions

Metastatic Malignant Solid Neoplasm

Interventions

DRUG: Copper Cu 64-DOTA-pembrolizumab
PROCEDURE: Positron Emission Tomography
RADIATION: Stereotactic Body Radiation Therapy

Sponsor

City of Hope Medical Center

Collaborators

[object Object]